Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight \>34 kg (75 lb) and of any race/ethnicity~* Able to swallow oral tablets whole~* Anticipated (likely to develop within 3-5 days) or documented neutropenia due to chemotherapy, chemotherapy for a new diagnosis of acute myelogenous leukemia (AML), or AML in first relapse; myelodysplastic syndromes (MDS) in transformation to AML; allogeneic hematopoietic stem cell transplant (HSCT) participants in the pre-engraftment period or in the post-engraftment period if they are receiving immunosuppressive therapy for graft versus host disease~Exclusion Criteria:~- Female must not be pregnant, must not intend to become pregnant~during the study, and must not be nursing~* History of hypersensitivity to azoles~* Moderate or severe liver dysfunction defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than three times the upper limit of normal (ULN), AND a total bilirubin level greater than two times the ULN~* Electrocardiogram (ECG) with corrected QTc interval greater than 500 msec~* Posaconazole within 10 days before study enrollment~* Receipt of systemic antifungal therapy within 30 days of study enrollment for reasons other than antifungal prophylaxis~* Evidence of known or suspected invasive or systemic fungal infection at baseline~* Known or suspected history of Gilbert's disease~* Creatinine clearance levels below 30 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posaconazole 200 mg (Type: EXPERIMENTAL): Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
- Posaconazole 300 mg (Type: EXPERIMENTAL): Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).